PDL BioPharma Inc (PDLI, Financial) files its latest 10-K with SEC for the fiscal year ended on December 31, 2017. PDL BioPharma Inc is engaged in the discovery of a new generation of targeted treatments for cancer and immunologic diseases. It focuses on intellectual property asset management, investing in new royalty bearing assets and maximizing value of its patent. PDL BioPharma Inc has a market cap of $456.843 million; its shares were traded at around $2.96 with a P/E ratio of 4.13 and P/S ratio of 1.48. PDL BioPharma Inc had annual average EBITDA growth of 2.10% over the past ten years.
For the last quarter PDL BioPharma Inc reported a revenue of $68.0 million, compared with the revenue of $66.49 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $320.1 million, an increase of 31% from last year. For the last five years PDL BioPharma Inc had an average revenue decline of 7.5% a year.
The reported diluted earnings per share was 71 cents for the year, an increase of 82.1% from previous year. Over the last five years PDL BioPharma Inc had an average EPS decline of 20% a year. The PDL BioPharma Inc enjoyed an operating margin of 60.54%, compared with the operating margin of 52.97% a year before. The 10-year historical median operating margin of PDL BioPharma Inc is 93.26%. The profitability rank of the company is 5 (out of 10).
At the end of the fiscal year, PDL BioPharma Inc has the cash and cash equivalents of $532.1 million, compared with $147.2 million in the previous year. The long term debt was $243.5 million, compared with $232.4 million in the previous year. The interest coverage to the debt is 9.6. PDL BioPharma Inc has a financial strength rank of 6 (out of 10).
At the current stock price of $2.96, PDL BioPharma Inc is traded at 49.1% discount to its historical median P/S valuation band of $5.82. The P/S ratio of the stock is 1.48, while the historical median P/S ratio is 2.89. The stock gained 37.04% during the past 12 months.
For the complete 20-year historical financial data of PDLI, click here.
